Functional Imaging — MCQs

Q: A 70-year-old male with recurrent prostate cancer post-prostatectomy has rising PSA (4.2 ng/mL) but negative conventional imaging. Which functional imaging modality would provide the highest detection rate for disease localization in this clinical scenario?

68Ga-PSMA PET-CT. ***68Ga-PSMA PET-CT*** - **68Ga-PSMA PET-CT** is currently the gold standard for detecting **biochemical recurrence** of prostate cancer, showing a detection rate of over 90% when PSA levels are >2 ng/mL. - It targets the **Prostate-Specific Membrane Antigen**, which is significantly overexpressed in prostate cancer cells, allowing for precise localization of both local recurrence and **distant metastases**. *In-111 Capromab pendetide scan* - This older imaging modality (ProstaScint) targets an **intracellular epitope** of PSMA, which is less accessible in viable, non-necrotic cells compared to the extracellular targets of modern tracers. - It has a much lower **sensitivity and specificity** compared to 68Ga-PSMA PET-CT and is rarely used in contemporary clinical practice. *18F-FDG PET-CT* - **18F-FDG** is generally not useful for prostate cancer because these tumors are typically slow-growing and have **low glucose metabolism** (low glycolytic rate). - It is primarily reserved for **aggressive, high-grade**, or neuroendocrine-differentiated prostate cancers that have lost the ability to express PSMA. *Tc-99m MDP bone scan* - This is a conventional imaging modality that detects **osteoblastic activity** rather than the cancer cells themselves, often resulting in low sensitivity at low PSA levels. - It is specifically limited to detecting **bone metastases** and cannot identify soft tissue recurrence or lymph node involvement in the pelvis.

Q: A 58-year-old presents with progressive cognitive decline. MRI brain is unremarkable. FDG-PET shows bilateral temporoparietal and posterior cingulate hypometabolism with relative sparing of sensorimotor cortex. Analyze these findings to determine the most likely diagnosis.

Alzheimer's disease. ***Alzheimer's disease*** - The classic FDG-PET findings for this condition involve bilateral **temporoparietal** and **posterior cingulate** hypometabolism while typically sparing the **sensorimotor cortex**. - This metabolic signature often appears during the **prodromal phase**, frequently preceding the structural **atrophy** seen on traditional MRI scans. *Normal pressure hydrocephalus* - On imaging, this condition is characterized by **ventriculomegaly** disproportionate to the degree of cortical atrophy, which is not described here. - Clinically, it presents with the classic triad of **gait disturbance**, **urinary incontinence**, and **dementia**, rather than isolated metabolic patterns on PET. *Frontotemporal dementia* - FDG-PET would typically demonstrate hypometabolism localized to the **frontal** and **anterior temporal lobes**, which differs from the posterior pattern seen in this case. - Early symptoms usually include significant **personality changes** or **behavioral disturbances** rather than generalized progressive cognitive decline alone. *Vascular dementia* - PET scanning usually shows a **focal or multifocal** "patchy" pattern of hypometabolism corresponding to areas of prior **infarction** or chronic ischemia. - Diagnosis is generally supported by MRI evidence of **lacunar infarcts**, **extensive white matter disease**, or territorial strokes.

Q: A 62-year-old male with lung cancer undergoes baseline PET-CT showing a 4 cm right upper lobe mass with SUVmax of 8.5. After 2 cycles of chemotherapy, repeat PET-CT shows the mass measures 3.5 cm with SUVmax of 3.2. Analyze the metabolic response according to PERCIST criteria.

Partial metabolic response. ***Partial metabolic response*** - According to **PERCIST** criteria, a reduction in **SULpeak** or **SUVmax** of **≥30%** is classified as a partial metabolic response. - In this case, the SUVmax decreased from **8.5 to 3.2**, which is a **62% reduction**, far exceeding the 30% threshold for response. *Progressive metabolic disease* - Defined by a **>30% increase** in SUVmax or the appearance of **new metabolic lesions**. - This patient showed a significant decrease in metabolic activity, contradicting a diagnosis of progression. *Stable metabolic disease* - This category applies when the change in SUVmax falls between a **30% decrease and a 30% increase**. - Since the metabolic activity dropped by 62%, the response is too significant to be labeled as stable. *Complete metabolic response* - Requires a total **disappearance of metabolic uptake** in all lesions, ideally dropping below the level of **background liver activity**. - While the uptake decreased significantly, a residual **SUVmax of 3.2** indicates persistent metabolic activity, preventing a classification of complete response.

Q: A 45-year-old woman with suspected temporal lobe epilepsy undergoes ictal SPECT with Tc-99m HMPAO. The scan shows increased tracer uptake in the left mesial temporal region. What is the clinical significance of this finding?

Indicates the seizure focus for potential surgical planning. ***Indicates the seizure focus for potential surgical planning*** - **Ictal SPECT** utilizes radiopharmaceuticals like **Tc-99m HMPAO**, which are sequestered in the brain during the first pass, capturing the **hyperperfusion** occurring at the **seizure focus**. - This functional imaging is critical for localized **epileptogenic zone** identification, especially when structural MRI is normal, to guide **surgical resection**. *Represents post-ictal hypoperfusion* - **Post-ictal** scans typically show decreased blood flow (**hypoperfusion**) in the area where the seizure originated, rather than increased uptake. - For accurate localization, the tracer must be injected as close to the **seizure onset** as possible to capture the hyperperfusion state. *Rules out epilepsy as a diagnosis* - An area of **increased tracer uptake** (hyperperfusion) during a seizure actually supports a diagnosis of **epilepsy** by identifying a functional focal abnormality. - **SPECT** is a tool used for localization in known or suspected epilepsy patients, not a definitive test to rule out the disorder itself. *Shows normal brain perfusion pattern* - A **normal perfusion pattern** would show symmetric uptake across both temporal lobes, without the focal **hyperperfusion** seen in this patient's left mesial region. - Focal increases in tracer concentration are indicative of **pathological neuronal overactivity** associated with ictal events.

Q: What is the primary principle behind BOLD (Blood Oxygen Level Dependent) contrast in functional MRI?

Paramagnetic properties of deoxyhemoglobin. ***Paramagnetic properties of deoxyhemoglobin*** - **Deoxyhemoglobin** acts as an endogenous contrast agent because it is **paramagnetic**, which creates local magnetic field inhomogeneities and decreases the **T2* signal**. - During neuronal activity, an oversupply of oxygenated blood (which is **diamagnetic**) flushes out the deoxyhemoglobin, leading to a relative increase in the **MR signal intensity**. *Increased water diffusion in active tissue* - This describes **Diffusion-Weighted Imaging (DWI)**, which measures the random motion of water molecules rather than blood oxygenation levels. - While **diffusion fMRI** is an experimental technique, it is distinct from the standard **BOLD contrast** mechanism which relies on hemodynamic changes. *Accumulation of gadolinium in active neurons* - **Gadolinium** is an exogenous (external) contrast agent used in conventional MRI to enhance visibility of vascularity or blood-brain barrier breakdown. - **BOLD imaging** is a non-invasive technique that does not require the injection of contrast agents like gadolinium to monitor brain activity. *Increased fat content in metabolically active tissue* - Neuronal activity is associated with changes in **glucose metabolism** and **blood flow**, not an increase in local fat or lipid concentration. - **Fat suppression** techniques are actually used in MRI to remove signals from adipose tissue to better visualize underlying structures.

Q: Which radiotracer is most commonly used for PET imaging in oncology?

18F-Fluorodeoxyglucose (18F-FDG). ***18F-Fluorodeoxyglucose (18F-FDG)*** - **18F-FDG** is a glucose analog that accumulates in **metabolically active** cells, making it the standard for detecting malignant tumors which exhibit high **glycolysis**. - It has an ideal half-life of approximately **110 minutes**, allowing for efficient diagnostic imaging and clinical distribution. *Technetium-99m* - This is the most common tracer for **SPECT** imaging and bone scans, not PET imaging, due to its **gamma emission** properties. - It does not measure **glucose metabolism**, which is the primary mechanism required for standard oncological PET scans. *Gallium-67* - Primarily used in the past for detecting **inflammation**, infections, or certain lymphomas via **SPECT** imaging. - It has a long half-life of 78 hours and relies on **transferrin binding** rather than the metabolic pathways used in PET/CT. *Iodine-131* - This isotope is specifically used for the diagnosis and treatment of **thyroid carcinoma** and hyperthyroidism. - It emits both **beta and gamma radiation**, making it more suitable for **radionuclide therapy** than routine PET diagnostic imaging.

Functional Imaging Indian Medical PG Practice Questions and MCQs

Question 1: A 48-year-old woman presents with suspected myocardial ischemia. Pharmacologic stress myocardial perfusion SPECT with Tc-99m sestamibi shows reversible perfusion defect in the inferior wall. Evaluate the optimal management approach based on this functional imaging finding.

A. Reassure patient as findings represent artifact
B. Start medical management without further investigation
C. Recommend coronary angiography for further evaluation and potential revascularization (Correct Answer)
D. Proceed directly to coronary artery bypass grafting

Explanation: ***Recommend coronary angiography for further evaluation and potential revascularization*** - A **reversible perfusion defect** on SPECT denotes **stress-induced ischemia** with viable myocardium, characterized by reduced tracer uptake during stress that normalizes at rest. - This finding indicates significant **coronary artery stenosis** (often >70%) and requires **coronary angiography** to define the anatomy and plan possible **percutaneous coronary intervention (PCI)**. *Reassure patient as findings represent artifact* - While **diaphragmatic attenuation** can cause inferior wall artifacts, a truly **reversible defect** (normal rest scan) is diagnostic of ischemia rather than a permanent artifact. - Attenuation artifacts typically present as **fixed defects** or are clarified using **ECG-gated SPECT** to check for normal wall motion. *Start medical management without further investigation* - Although medical therapy is a pillar of CAD treatment, a documented **reversible defect** in a symptomatic patient warrants anatomical assessment to evaluate the risk of **major adverse cardiovascular events (MACE)**. - Management solely with drugs is insufficient for patients with high-risk ischemia patterns on **functional imaging** who may benefit from revascularization. *Proceed directly to coronary artery bypass grafting* - **Coronary artery bypass grafting (CABG)** is a surgical intervention that requires prior visualization of coronary anatomy via angiography to determine the extent of disease (e.g., **triple-vessel** or **left main disease**). - It is premature to provide surgical referral before confirming the **syntax score** or the suitability of the lesions for less invasive procedures like **angioplasty**.

Question 2: A 70-year-old male with recurrent prostate cancer post-prostatectomy has rising PSA (4.2 ng/mL) but negative conventional imaging. Which functional imaging modality would provide the highest detection rate for disease localization in this clinical scenario?

A. 68Ga-PSMA PET-CT (Correct Answer)
B. In-111 Capromab pendetide scan
C. 18F-FDG PET-CT
D. Tc-99m MDP bone scan

Explanation: ***68Ga-PSMA PET-CT*** - **68Ga-PSMA PET-CT** is currently the gold standard for detecting **biochemical recurrence** of prostate cancer, showing a detection rate of over 90% when PSA levels are >2 ng/mL. - It targets the **Prostate-Specific Membrane Antigen**, which is significantly overexpressed in prostate cancer cells, allowing for precise localization of both local recurrence and **distant metastases**. *In-111 Capromab pendetide scan* - This older imaging modality (ProstaScint) targets an **intracellular epitope** of PSMA, which is less accessible in viable, non-necrotic cells compared to the extracellular targets of modern tracers. - It has a much lower **sensitivity and specificity** compared to 68Ga-PSMA PET-CT and is rarely used in contemporary clinical practice. *18F-FDG PET-CT* - **18F-FDG** is generally not useful for prostate cancer because these tumors are typically slow-growing and have **low glucose metabolism** (low glycolytic rate). - It is primarily reserved for **aggressive, high-grade**, or neuroendocrine-differentiated prostate cancers that have lost the ability to express PSMA. *Tc-99m MDP bone scan* - This is a conventional imaging modality that detects **osteoblastic activity** rather than the cancer cells themselves, often resulting in low sensitivity at low PSA levels. - It is specifically limited to detecting **bone metastases** and cannot identify soft tissue recurrence or lymph node involvement in the pelvis.

Question 3: A 58-year-old presents with progressive cognitive decline. MRI brain is unremarkable. FDG-PET shows bilateral temporoparietal and posterior cingulate hypometabolism with relative sparing of sensorimotor cortex. Analyze these findings to determine the most likely diagnosis.

A. Normal pressure hydrocephalus
B. Frontotemporal dementia
C. Alzheimer's disease (Correct Answer)
D. Vascular dementia

Explanation: ***Alzheimer's disease*** - The classic FDG-PET findings for this condition involve bilateral **temporoparietal** and **posterior cingulate** hypometabolism while typically sparing the **sensorimotor cortex**. - This metabolic signature often appears during the **prodromal phase**, frequently preceding the structural **atrophy** seen on traditional MRI scans. *Normal pressure hydrocephalus* - On imaging, this condition is characterized by **ventriculomegaly** disproportionate to the degree of cortical atrophy, which is not described here. - Clinically, it presents with the classic triad of **gait disturbance**, **urinary incontinence**, and **dementia**, rather than isolated metabolic patterns on PET. *Frontotemporal dementia* - FDG-PET would typically demonstrate hypometabolism localized to the **frontal** and **anterior temporal lobes**, which differs from the posterior pattern seen in this case. - Early symptoms usually include significant **personality changes** or **behavioral disturbances** rather than generalized progressive cognitive decline alone. *Vascular dementia* - PET scanning usually shows a **focal or multifocal** "patchy" pattern of hypometabolism corresponding to areas of prior **infarction** or chronic ischemia. - Diagnosis is generally supported by MRI evidence of **lacunar infarcts**, **extensive white matter disease**, or territorial strokes.

Question 4: A 62-year-old male with lung cancer undergoes baseline PET-CT showing a 4 cm right upper lobe mass with SUVmax of 8.5. After 2 cycles of chemotherapy, repeat PET-CT shows the mass measures 3.5 cm with SUVmax of 3.2. Analyze the metabolic response according to PERCIST criteria.

A. Progressive metabolic disease
B. Stable metabolic disease
C. Partial metabolic response (Correct Answer)
D. Complete metabolic response

Explanation: ***Partial metabolic response*** - According to **PERCIST** criteria, a reduction in **SULpeak** or **SUVmax** of **≥30%** is classified as a partial metabolic response. - In this case, the SUVmax decreased from **8.5 to 3.2**, which is a **62% reduction**, far exceeding the 30% threshold for response. *Progressive metabolic disease* - Defined by a **>30% increase** in SUVmax or the appearance of **new metabolic lesions**. - This patient showed a significant decrease in metabolic activity, contradicting a diagnosis of progression. *Stable metabolic disease* - This category applies when the change in SUVmax falls between a **30% decrease and a 30% increase**. - Since the metabolic activity dropped by 62%, the response is too significant to be labeled as stable. *Complete metabolic response* - Requires a total **disappearance of metabolic uptake** in all lesions, ideally dropping below the level of **background liver activity**. - While the uptake decreased significantly, a residual **SUVmax of 3.2** indicates persistent metabolic activity, preventing a classification of complete response.

Question 5: A 45-year-old woman with suspected temporal lobe epilepsy undergoes ictal SPECT with Tc-99m HMPAO. The scan shows increased tracer uptake in the left mesial temporal region. What is the clinical significance of this finding?

A. Indicates the seizure focus for potential surgical planning (Correct Answer)
B. Represents post-ictal hypoperfusion
C. Rules out epilepsy as a diagnosis
D. Shows normal brain perfusion pattern

Explanation: ***Indicates the seizure focus for potential surgical planning*** - **Ictal SPECT** utilizes radiopharmaceuticals like **Tc-99m HMPAO**, which are sequestered in the brain during the first pass, capturing the **hyperperfusion** occurring at the **seizure focus**. - This functional imaging is critical for localized **epileptogenic zone** identification, especially when structural MRI is normal, to guide **surgical resection**. *Represents post-ictal hypoperfusion* - **Post-ictal** scans typically show decreased blood flow (**hypoperfusion**) in the area where the seizure originated, rather than increased uptake. - For accurate localization, the tracer must be injected as close to the **seizure onset** as possible to capture the hyperperfusion state. *Rules out epilepsy as a diagnosis* - An area of **increased tracer uptake** (hyperperfusion) during a seizure actually supports a diagnosis of **epilepsy** by identifying a functional focal abnormality. - **SPECT** is a tool used for localization in known or suspected epilepsy patients, not a definitive test to rule out the disorder itself. *Shows normal brain perfusion pattern* - A **normal perfusion pattern** would show symmetric uptake across both temporal lobes, without the focal **hyperperfusion** seen in this patient's left mesial region. - Focal increases in tracer concentration are indicative of **pathological neuronal overactivity** associated with ictal events.

Question 6: A 55-year-old male with suspected Parkinson's disease undergoes DaTscan (Ioflupane I-123 SPECT). The scan shows reduced uptake in bilateral striatum with comma-shaped appearance. What is the most appropriate interpretation?

A. Normal scan ruling out Parkinson's disease
B. Consistent with presynaptic dopaminergic deficit supporting Parkinsonian syndrome (Correct Answer)
C. Indicates essential tremor
D. Diagnostic of drug-induced parkinsonism

Explanation: ***Consistent with presynaptic dopaminergic deficit supporting Parkinsonian syndrome*** - A **DaTscan** measures the density of **presynaptic dopamine transporters (DAT)**; reduced uptake indicates a loss of dopaminergic neurons in the **striatum**. - This pattern confirms a **Parkinsonian syndrome** (such as Parkinson's disease, **Multiple System Atrophy**, or Progressive Supranuclear Palsy) by showing neurodegeneration. *Normal scan ruling out Parkinson's disease* - A normal scan would display high symmetric uptake with a distinct **full comma or crescent shape** in the striatum. - **Reduced uptake** is fundamentally abnormal and indicates the presence of an underlying neurodegenerative process. *Indicates essential tremor* - In **essential tremor**, the presynaptic dopaminergic system remains intact, resulting in a **normal DaTscan**. - This imaging modality is specifically used to differentiate essential tremor from **neurodegenerative parkinsonism**. *Diagnostic of drug-induced parkinsonism* - **Drug-induced parkinsonism** is caused by postsynaptic dopamine receptor blockade, leaving the **presynaptic transporters** unaffected. - Consequently, the DaTscan in drug-induced cases would be **normal**, unlike the reduced uptake seen in this patient.

Question 7: Why does 18F-FDG accumulation occur in inflammatory lesions despite PET being primarily used for cancer detection?

A. Inflammatory cells have no glucose metabolism
B. FDG is specific only for malignant cells
C. Activated macrophages and neutrophils have increased glucose metabolism (Correct Answer)
D. Inflammation causes decreased blood flow reducing FDG delivery

Explanation: ***Activated macrophages and neutrophils have increased glucose metabolism*** - **Inflammatory cells** in a state of activation, such as **macrophages** and **neutrophils**, show a significant spike in **glucose metabolism** and the expression of **GLUT transporters**. - This high metabolic demand leads to the intense uptake of **18F-FDG**, causing it to accumulate in non-malignant, active inflammatory lesions. *Inflammatory cells have no glucose metabolism* - Inflammatory cells are metabolically active and rely heavily on **glycolysis** for energy during an immune response. - Absence of glucose metabolism would result in no **FDG uptake**, which contradicts observed clinical **PET findings** in infections. *FDG is specific only for malignant cells* - **18F-FDG** is a glucose analog and is not specific to cancer; it is a marker of **metabolic activity** in any tissue. - This lack of specificity is a known **pitfall in PET imaging**, as it can lead to false-positive results in inflammatory or infectious conditions. *Inflammation causes decreased blood flow reducing FDG delivery* - Inflammation typically leads to **vasodilation** and **increased capillary permeability**, which actually **increases** the delivery of radiopharmaceuticals to the site. - Increased perfusion combined with high cellular uptake is what makes inflammatory sites appear as **hot spots** on a PET scan.

Question 8: How does diffusion-weighted imaging (DWI) detect acute stroke earlier than conventional MRI sequences?

A. By detecting increased blood flow to ischemic tissue
B. By measuring restricted water diffusion due to cytotoxic edema (Correct Answer)
C. By identifying hemorrhagic transformation
D. By detecting breakdown of blood-brain barrier

Explanation: ***By measuring restricted water diffusion due to cytotoxic edema*** - **DWI** is sensitive to the **Brownian motion** of water molecules; during ischemia, the failure of **Na+/K+ ATPase pumps** leads to **cytotoxic edema**. - This intracellular water shift results in **restricted diffusion**, which appears as a hyperintense signal within minutes of stroke onset, far earlier than seen on **CT** or **T2-weighted MRI**. *By detecting increased blood flow to ischemic tissue* - Ischemic stroke is characterized by **decreased blood flow** (hypoperfusion), not an increase, in the affected vascular territory. - Techniques like **Perfusion-Weighted Imaging (PWI)** are used to measure blood flow, not standard DWI sequences. *By identifying hemorrhagic transformation* - Hemorrhagic transformation is best detected using **CT scans** or specific MRI sequences like **gradient echo (GRE)** or **Susceptibility-Weighted Imaging (SWI)**. - DWI is utilized to identify the **ischemic core**, while blood products typically create a signal dropout or "bloom" on susceptibility sequences. *By detecting breakdown of blood-brain barrier* - Breakdown of the **blood-brain barrier** leads to **vasogenic edema**, which typically occurs hours to days after the initial insult. - This process is better visualized using **contrast-enhanced T1-weighted imaging**, whereas DWI focuses on the immediate **cytotoxic** phase of cell injury.

Question 9: What is the primary principle behind BOLD (Blood Oxygen Level Dependent) contrast in functional MRI?

A. Increased water diffusion in active tissue
B. Paramagnetic properties of deoxyhemoglobin (Correct Answer)
C. Accumulation of gadolinium in active neurons
D. Increased fat content in metabolically active tissue

Explanation: ***Paramagnetic properties of deoxyhemoglobin*** - **Deoxyhemoglobin** acts as an endogenous contrast agent because it is **paramagnetic**, which creates local magnetic field inhomogeneities and decreases the **T2* signal**. - During neuronal activity, an oversupply of oxygenated blood (which is **diamagnetic**) flushes out the deoxyhemoglobin, leading to a relative increase in the **MR signal intensity**. *Increased water diffusion in active tissue* - This describes **Diffusion-Weighted Imaging (DWI)**, which measures the random motion of water molecules rather than blood oxygenation levels. - While **diffusion fMRI** is an experimental technique, it is distinct from the standard **BOLD contrast** mechanism which relies on hemodynamic changes. *Accumulation of gadolinium in active neurons* - **Gadolinium** is an exogenous (external) contrast agent used in conventional MRI to enhance visibility of vascularity or blood-brain barrier breakdown. - **BOLD imaging** is a non-invasive technique that does not require the injection of contrast agents like gadolinium to monitor brain activity. *Increased fat content in metabolically active tissue* - Neuronal activity is associated with changes in **glucose metabolism** and **blood flow**, not an increase in local fat or lipid concentration. - **Fat suppression** techniques are actually used in MRI to remove signals from adipose tissue to better visualize underlying structures.

Question 10: Which radiotracer is most commonly used for PET imaging in oncology?

A. Technetium-99m
B. 18F-Fluorodeoxyglucose (18F-FDG) (Correct Answer)
C. Gallium-67
D. Iodine-131

Explanation: ***18F-Fluorodeoxyglucose (18F-FDG)*** - **18F-FDG** is a glucose analog that accumulates in **metabolically active** cells, making it the standard for detecting malignant tumors which exhibit high **glycolysis**. - It has an ideal half-life of approximately **110 minutes**, allowing for efficient diagnostic imaging and clinical distribution. *Technetium-99m* - This is the most common tracer for **SPECT** imaging and bone scans, not PET imaging, due to its **gamma emission** properties. - It does not measure **glucose metabolism**, which is the primary mechanism required for standard oncological PET scans. *Gallium-67* - Primarily used in the past for detecting **inflammation**, infections, or certain lymphomas via **SPECT** imaging. - It has a long half-life of 78 hours and relies on **transferrin binding** rather than the metabolic pathways used in PET/CT. *Iodine-131* - This isotope is specifically used for the diagnosis and treatment of **thyroid carcinoma** and hyperthyroidism. - It emits both **beta and gamma radiation**, making it more suitable for **radionuclide therapy** than routine PET diagnostic imaging.

Question 11: Which of the following is used to differentiate tumor recurrence and radiation necrosis?

A. PET scan (Correct Answer)
B. MRI
C. 3D CT
D. USG

Explanation: ### Explanation The differentiation between **tumor recurrence** and **radiation necrosis** is a classic diagnostic challenge because both entities appear remarkably similar on conventional structural imaging (like MRI or CT). **1. Why PET scan is the correct answer:** The distinction relies on **metabolic activity** rather than anatomy. * **Tumor Recurrence:** Malignant cells are hypermetabolic and demonstrate high glucose uptake. On a **18F-FDG PET scan**, recurrence shows "hot spots" (increased tracer uptake). * **Radiation Necrosis:** This represents dead tissue and inflammatory changes following radiotherapy. It is metabolically inactive or hypometabolic, appearing as "cold spots" (decreased tracer uptake) on PET. * *Note:* Advanced PET tracers like **11C-Methionine** or **18F-FET** (Fluoroethyltyrosine) are even more specific than FDG for brain tumors. **2. Why other options are incorrect:** * **MRI (Conventional):** While MRI is the gold standard for initial diagnosis, both recurrence and necrosis show contrast enhancement and perilesional edema, making them indistinguishable on routine T1/T2 sequences. (Note: MR Spectroscopy/Perfusion can help, but PET remains the classic functional answer). * **3D CT:** CT provides excellent bony detail but lacks the soft tissue resolution and functional data required to assess tissue viability or metabolism. * **USG:** Ultrasound has no role in intracranial imaging in adults due to the skull barrier and lacks the sensitivity for metabolic differentiation. **High-Yield Clinical Pearls for NEET-PG:** * **MR Spectroscopy (MRS):** In tumor recurrence, there is **Increased Choline** (cell membrane turnover) and **Decreased NAA** (neuronal loss). * **Cold vs. Hot:** Radiation necrosis = Cold on PET; Tumor recurrence = Hot on PET. * **Thallium-201 SPECT:** Another functional modality used for this purpose; tumors are Thallium-positive, while necrosis is Thallium-negative.

Question 12: MRI is not better than CT for the detection of which of the following?

A. Ligament injury
B. Soft tissue tumors
C. Meningeal pathology
D. Calcified lesions (Correct Answer)

Explanation: **Explanation:** The correct answer is **D. Calcified lesions**. **Why CT is superior for Calcification:** Computed Tomography (CT) is based on X-ray attenuation. Calcium has a high atomic number, making it highly radiopaque (hyperdense/white) on CT. In contrast, MRI relies on proton (hydrogen) density. Calcified lesions contain very few mobile protons, resulting in a "signal void" (black appearance). Because many other structures (like cortical bone or rapidly flowing blood) also appear black on MRI, it is difficult to differentiate or quantify calcification using standard MRI sequences. Therefore, CT remains the **gold standard** for detecting intracranial calcifications, renal stones, and osteoid matrix in tumors. **Analysis of Incorrect Options:** * **A. Ligament injury:** MRI is the modality of choice due to its superior **spatial and contrast resolution**, allowing visualization of collagenous structures against fat and fluid. * **B. Soft tissue tumors:** MRI provides excellent **soft tissue characterization**, helping to define tumor margins, neurovascular involvement, and tissue composition (fat, blood, or necrosis) better than CT. * **C. Meningeal pathology:** MRI (especially post-gadolinium T1 sequences) is far more sensitive than CT for detecting leptomeningeal enhancement, dural metastases, or inflammatory changes. **High-Yield Clinical Pearls for NEET-PG:** * **Hyperacute Stroke:** Non-contrast CT is the initial investigation to rule out hemorrhage, but **Diffusion-Weighted Imaging (DWI) MRI** is the most sensitive for early ischemia. * **Posterior Fossa:** MRI is superior to CT because CT is prone to "bone hardening artifacts" in the posterior fossa. * **Susceptibility Weighted Imaging (SWI):** This specific MRI sequence is used to detect "blood or bone" (calcium vs. hemorrhage), but CT is still preferred for primary detection of calcification.

Question 13: What does PET stand for?

A. Positive electron tomography
B. Proton-electron therapy
C. Positron emission tomography (Correct Answer)
D. Photon emitting tomography

Explanation: **Explanation:** **Positron Emission Tomography (PET)** is a functional nuclear medicine imaging technique that detects gamma rays emitted indirectly by a positron-emitting radionuclide (tracer). The most common tracer used is **18F-Fluorodeoxyglucose (FDG)**, a glucose analog. 1. **Why Option C is Correct:** The process begins when a radioactive tracer undergoes **beta-plus decay**, emitting a **positron** (the antimatter counterpart of an electron). This positron travels a short distance before colliding with an electron in the tissue. This collision results in an **annihilation event**, producing two 511 keV photons (gamma rays) that travel in exactly opposite directions (180°). The PET scanner detects these coincident photons to create a 3D image of metabolic activity. 2. **Why Other Options are Incorrect:** * **Option A:** "Positive electron" is a descriptive term for a positron, but it is not the formal name of the modality. * **Option B:** PET is a diagnostic imaging tool, not a "therapy" (though it guides therapy). * **Option D:** While photons are emitted, the specific mechanism is the emission of a positron leading to photon production; "Photon emitting tomography" is too vague and could technically describe SPECT. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** PET measures **metabolic activity**, whereas CT/MRI measure anatomy. * **Standard Uptake Value (SUV):** A semi-quantitative measure used to differentiate malignant (high SUV) from benign lesions. * **Physiological Uptake:** Normal high FDG uptake is seen in the **brain** (high glucose requirement), **heart**, and **urinary tract** (excretion path). * **Clinical Use:** Primarily used for cancer staging, monitoring treatment response, and identifying myocardial viability.

Practice by Chapter

Principles of Functional Imaging

Practice Questions

Functional MRI

Practice Questions

Diffusion and Perfusion Imaging

Practice Questions

Spectroscopy

Practice Questions

PET and SPECT Functional Imaging

Practice Questions

Functional Imaging in Neurology

Practice Questions

Functional Imaging in Oncology

Practice Questions

Functional Imaging in Cardiology

Practice Questions

Dynamic Contrast-Enhanced Imaging

Practice Questions

Quantitative Imaging Biomarkers

Practice Questions

Integration of Functional and Anatomical Imaging

Practice Questions

Emerging Techniques in Functional Imaging

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free